|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Li CI, Uribe DJ and Daling JR: Clinical
characteristics of different histologic types of breast cancer. Br
J Cancer. 93:1046–1052. 2005.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sgroi DC: Preinvasive breast cancer. Annu
Rev Pathol. 5:193–221. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Espina V and Liotta LA: What is the
malignant nature of human ductal carcinoma in situ? Nat Rev Cancer.
11:68–75. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Chagpar AB, McMasters KM, Sahoo S and
Edwards MJ: Does ductal carcinoma in situ accompanying invasive
carcinoma affect prognosis? Surgery. 146:561–567. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wong H, Lau S, Yau T, Cheung P and Epstein
RJ: Presence of an in situ component is associated with reduced
biological aggressiveness of size-matched invasive breast cancer.
Br J Cancer. 102:1391–1396. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kole AJ, Park HS, Johnson SB, Kelly JR,
Moran MS and Patel AA: Overall survival is improved when DCIS
accompanies invasive breast cancer. Sci Rep. 9(9934)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cowell CF, Weigelt B, Sakr RA, Ng CK,
Hicks J, King TA and Reis-Filho JS: Progression from ductal
carcinoma in situ to invasive breast cancer: Revisited. Mol Oncol.
7:859–869. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lesurf R, Aure MR, Mørk HH and Vitelli V:
Oslo Breast Cancer Research Consortium (OSBREAC). Lundgren S,
Børresen-Dale AL, Kristensen V, Wärnberg F, Hallett M and Sørlie T:
Molecular features of subtype-specific progression from ductal
carcinoma in situ to invasive breast cancer. Cell Rep.
16:1166–1179. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chen H, Bai F, Wang M, Zhang M, Zhang P
and Wu K: The prognostic significance of co-existence ductal
carcinoma in situ in invasive ductal breast cancer: A large
population-based study and a matched case-control analysis. Ann
Transl Med. 7(484)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Galon J, Angell HK, Bedognetti D and
Marincola FM: The continuum of cancer immunosurveillance:
Prognostic, predictive, and mechanistic signatures. Immunity.
39:11–26. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Whiteside TL: Tumor-infiltrating
lymphocytes and their role in solid tumor progression. Exp Suppl.
113:89–106. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kashiwagi S, Asano Y, Goto W, Takada K,
Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Ohsawa M,
et al: Using TILs to predict therapeutic effect of chemotherapy
(Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive breast
cancer. Anticancer Res. 37:5623–5630. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Denkert C, von Minckwitz G, Darb-Esfahani
S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen
F, Furlanetto J, et al: Tumour-infiltrating lymphocytes and
prognosis in different subtypes of breast cancer: A pooled analysis
of 3771 patients treated with neoadjuvant therapy. Lancet Oncol.
19:40–50. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Giuliano AE, Connolly JL, Edge SB,
Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and
Hortobagyi GN: Breast cancer-major changes in the American Joint
Committee on Cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:290–303. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shao N, Xie C, Shi Y, Ye R, Long J, Shi H,
Shan Z, Thompson AM and Lin Y: Comparison of the 7th and 8th
edition of American Joint Committee on Cancer (AJCC) staging
systems for breast cancer patients: A Surveillance, Epidemiology
and End Results (SEER) Analysis. Cancer Manag Res. 11:1433–1442.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lopez Gordo S, Blanch Falp J, Lopez-Gordo
E, Just Roig E, Encinas Mendez J and Seco Calvo J: Influence of
ductal carcinoma in situ on the outcome of invasive breast cancer.
A prospective cohort study. Int J Surg. 63:98–106. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Goh CW, Wu J, Ding S, Lin C, Chen X, Huang
O, Chen W, Li Y, Shen K and Zhu L: Invasive ductal carcinoma with
coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive
ductal carcinoma (IDC): A comparison of clinicopathological
characteristics, molecular subtypes, and clinical outcomes. J
Cancer Res Clin Oncol. 145:1877–1886. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhou S, Shi Y, Huang Z, Teng Y and Xing W:
Does the presence of ductal carcinoma in situ affect prognostic
outcomes after neoadjuvant therapy in invasive ductal carcinoma of
the breast? Clin Oncol (R Coll Radiol). 40(103781)2025.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Liu Y and Yu T: Clinicopathological
characteristics and prognosis of triple-negative breast cancer
invasive ductal carcinoma with ductal carcinoma in situ. J Cancer
Res Clin Oncol. 149:11181–11191. 2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lam BM and Verrill C: Clinical
significance of tumour-infiltrating B lymphocytes (TIL-Bs) in
breast cancer: A systematic literature review. Cancers (Basel).
15(1164)2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Loi S, Michiels S, Salgado R, Sirtaine N,
Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V,
Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in
triple negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: Results from the FinHER trial. Ann
Oncol. 25:1544–1550. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Schüler K, Bethmann D, Kaufhold S, Hartung
C, Stückrath K, Lantzsch T, Uleer C, Hanf V, Peschel S, John J, et
al: Prognostic value of tumour-infiltrating lymphocytes in an
unselected cohort of breast cancer patients. Diagnostics (Basel).
12(2527)2022.PubMed/NCBI View Article : Google Scholar
|
